Aurealis Therapeutics Is A Swiss Nordic Synthetic Biology Company Focused On Developing Multi Target Cell And Gene Therapiesthe Company Aims To Address Significant Medical Needs In Chronic Woundscancersand Inflammatory Diseasestheir Mission Is To Create Curative Therapies That Enhance Patient Outcomes Through A Unique Multi Target Therapy Platform The Platform Utilizes Genetically Modified Lactic Acid Bacteria To Produce Various Therapeutic Proteinsincluding Cytokinesgrowth Factorsand Antibody Fragmentsthis Innovative Approach Is Designed To Modulate The Tissue Microenvironment And Effectively Treat Complex Diseasesaurealis Therapeutics Has A Product Pipeline That Includes Therapies For Diabetic Foot Ulcersovarian Cancerbladder Cancerand Inflammatory Conditionsone Of Their Key Productsaup 16Has A Licensing Agreement In China Valued At $139 Million And Is Approved For A Phase 2 Study On Diabetic Foot Ulcers The Company Is Led By A Team Of Experienced Professionals And Aims To Establish Strategic Partnerships To Enhance The Availability Of Their Therapies Globallytheir Vision Includes Generating Robust Clinical Data To Support The Safety And Efficacy Of Their Treatmentsultimately Benefiting Patients Worldwide
